Silver Oak Securities Incorporated Invests $220,000 in AtriCure, Inc. (NASDAQ:ATRC)

Silver Oak Securities Incorporated acquired a new stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 7,278 shares of the medical device company's stock, valued at approximately $220,000.

Other institutional investors have also recently bought and sold shares of the company. State Street Corp raised its position in AtriCure by 4.9% in the 3rd quarter. State Street Corp now owns 1,344,856 shares of the medical device company's stock valued at $37,710,000 after purchasing an additional 63,002 shares during the last quarter. Geode Capital Management LLC raised its position in shares of AtriCure by 2.9% during the third quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company's stock worth $32,326,000 after acquiring an additional 32,676 shares during the last quarter. Atom Investors LP bought a new stake in shares of AtriCure during the third quarter worth $1,741,000. SG Americas Securities LLC bought a new stake in shares of AtriCure during the third quarter worth $488,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of AtriCure by 31.5% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company's stock worth $14,038,000 after acquiring an additional 119,929 shares during the last quarter. Institutional investors own 99.11% of the company's stock.

AtriCure Trading Down 6.5 %

NASDAQ:ATRC traded down $2.77 on Thursday, reaching $39.59. The company's stock had a trading volume of 1,284,964 shares, compared to its average volume of 608,585. AtriCure, Inc. has a 1-year low of $18.94 and a 1-year high of $43.11. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62. The firm has a market cap of $1.93 billion, a PE ratio of -47.70 and a beta of 1.46. The business's 50-day moving average price is $35.52 and its two-hundred day moving average price is $31.17.

Wall Street Analysts Forecast Growth

ATRC has been the subject of a number of recent research reports. UBS Group boosted their target price on AtriCure from $35.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. JMP Securities restated a "market outperform" rating and set a $60.00 target price on shares of AtriCure in a research report on Monday. JPMorgan Chase & Co. boosted their target price on AtriCure from $40.00 to $51.00 and gave the stock an "overweight" rating in a research report on Tuesday. Piper Sandler boosted their target price on AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a research report on Thursday. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $51.00 price objective on shares of AtriCure in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $51.56.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.